Thus, GBA mutations or a reduction in GCase activity through pharmacological or genetic approaches have resulted in the accumulation of α-synuclein in several in vivo and in vitro models, similar to what is observed in PD-GBA brains [104,105,106,107,108,109]. The gene discussed is GBA1; the disease is Parkinson disease.